State Street Corporation reported strong Q2 results driven by a 70% year-over-year increase in earnings per share (EPS), supported by over 20% growth in assets under management (AUM) and robust non-interest income. The company raised its full-year guidance and reaffirmed midterm earnings targets, aiming for a mid-20% return on tangible common equity (ROTCE) and projecting EPS of $16.5–$17 by 2028–2029. Additionally, its Series G preferred stock offers a 6.8% yield with low payout risk and potential capital gains if called. These results highlight State Street's solid fee-driven business model and attractive investment potential despite a premium valuation.
The global clinical trial supplies market is projected to grow from $5.7 billion in 2025 to $10.7 billion by 2033, at an 8.4% CAGR. This growth is driven by increased R&D investments, rising chronic diseases, and the expansion of biologics, personali...
Starlink Mobile, launched by VEON Ltd. across Ukraine, Kazakhstan, and Bangladesh, has connected over 11 million users in less than a year. The service enables existing 4G phones to access satellite connectivity where terrestrial signals are unavaila...
Medallion Financial Corp. announced it will repurchase $15 million in trust preferred securities from BIMIZCI Fund LLC at 73.66% of face value, costing about $11.05 million plus accrued distributions. This deal includes a five-year standstill agreeme...
Belite Bio, a clinical-stage drug developer focused on retinal diseases, has been approved to move its stock listing from the Nasdaq Capital Market to the Nasdaq Global Select Market, the highest tier on Nasdaq. This uplisting reflects the company's ...
Heineken N.V. has repurchased a total of 8,865,521 shares under the second tranche of its €1.5 billion share buyback program, spending €629.4 million as of October 16, 2026. This includes shares bought on the exchange and from Heineken Holding N.V. T...
